An endogenous aryl hydrocarbon receptor ligand inhibits proliferation and migration of human ovarian cancer cells

Cancer Letters

Volumn 340, Issue 1, 2013, Pages 63-71

  Wang, Kai ^a,b   Li, Yan ^b   Jiang, Yi Zhou ^b   Dai, Cai Feng ^b,c   Patankar, Manish S ^b   Song, Jia Sheng ^d   Zheng, Jing ^b,e  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c SHANDONG UNIVERSITY   (China)

^d AhR Pharmaceuticals Inc   (United States)

^e GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Aryl hydrocarbon receptor; Growth; ITE; Ovarian cancer cells

Indexed keywords

2 (1'H INDOLE 3' CARBONYL)THIAZOLE 4 CARBOXYLIC ACID METHYL ESTER; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A1; MESSENGER RNA; MIGRATION INHIBITION FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG TOLERABILITY; EPITHELIUM CELL; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MIGRATION INHIBITION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ARYL HYDROCARBON RECEPTOR; GROWTH; ITE; OVARIAN CANCER CELLS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYTOCHROME P-450 CYP1A1; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDOLES; LIGANDS; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; RECEPTORS, ARYL HYDROCARBON; THIAZOLES; TISSUE ARRAY ANALYSIS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84883814521     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.06.026     Document Type: Article

References (41)

1. Bast R.C., Hennessy B., Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 2009, 9:415-428.
2. Yap T.A., Carden C.P., Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer 2009, 9:167-181.
3. Safe S., McDougal A. Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers. Int. J. Oncol. 2002, 20:1123-1128.
4. Fujii-Kuriyama Y., Kawajiri K. Molecular mechanisms of the physiological functions of the aryl hydrocarbon (dioxin) receptor, a multifunctional regulator that senses and responds to environmental stimuli. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 2010, 86:40-53.
5. Clapp R.W., Jacobs M.M., Loechler E.L. Environmental and occupational causes of cancer: new evidence 2005-2007. Rev. Environ. Health 2008, 23:1-37.
6. Diamanti-Kandarakis E., Bourguignon J.P., Giudice L.C., Hauser R., Prins G.S., Soto A.M., Zoeller R.T., Gore A.C. Endocrine-disrupting chemicals: an endocrine society scientific statement. Endocr. Rev. 2009, 30:242-293.
7. Hernandez-Ochoa I., Karman B.N., Flaws J.A. The role of the aryl hydrocarbon receptor in the female reproductive system. Biochem. Pharmacol. 2009, 77:547-559.
8. Ahmed S., Valen E., Sandelin A., Matthews J. Dioxin increases the interaction between aryl hydrocarbon receptor and estrogen receptor alpha at human promoters. Toxicol. Sci. 2009, 111:254-266.
9. Shanle E.K., Xu W. Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. Chem. Res. Toxicol. 2011, 24:6-19.
10. Cunat S., Hoffmann P., Pujol P. Estrogens and epithelial ovarian cancer. Gynecol. Oncol. 2004, 94:25-32.
11. Consonni D., Pesatori A.C., Zocchetti C., Sindaco R., D'Oro L.C., Rubagotti M., Bertazzi P.A. Mortality in a population exposed to dioxin after the Seveso, Italy, accident in 1976: 25 years of follow-up. Am. J. Epidemiol. 2008, 167:847-858.
12. Bertazzi P.A., Zocchetti C., Guercilena S., Consonni D., Tironi A., Landi M.T., Pesatori A.C. Dioxin exposure and cancer risk: a 15-year mortality study after the "Seveso accident". Epidemiology 1997, 8:646-652.
13. Viel J.F., Clement M.C., Hagi M., Grandjean S., Challierl B., Danzon A. Dioxin emissions from a municipal solid waste incinerator and risk of invasive breast cancer: a population-based case-control study with GIS-derived exposure. Int. J. Health Geogr. 2008, 7:4.
14. Lin P., Chang H., Tsai W.T., Wu M.H., Liao Y.S., Chen J.T., Su J.M. Overexpression of aryl hydrocarbon receptor in human lung carcinomas. Toxicol. Pathol. 2003, 31:22-30.
15. Steenland K., Bertazzi P., Baccarelli A., Kogevinas M. Dioxin revisited: developments since the, 1997 IARC classification of dioxin as a human carcinogen. Environ. Health. Perspect. 2004, 112:1265-1268.
16. Wong P., Li W., Vogel C., Matsumura F. Characterization of MCF mammary epithelial cells overexpressing the arylhydrocarbon receptor (AhR). BMC Cancer 2009, 9:234.
17. Kim J.H., Kim H., Lee K.Y., Kang J.W., Lee K.H., Park S.Y., Yoon H.I., Jheon S.H., Sung S.W., Hong Y.C. Aryl hydrocarbon receptor gene polymorphisms affect lung cancer risk. Lung Cancer 2007, 56:9-15.
18. Wormke M., Castro-Rivera E., Chen I., Safe S. Estrogen and aryl hydrocarbon receptor expression and crosstalk in human Ishikawa endometrial cancer cells. J. Steroid. Biochem. Mol. Biol. 2000, 72:197-207.
19. Fan Y., Boivin G.P., Knudsen E.S., Nebert D.W., Xia Y., Puga A. The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res. 2010, 70:212-220.
20. Hall J.M., Barhoover M.A., Kazmin D., McDonnell D.P., Greenlee W.F., Thomas R.S. Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Mol. Endocrinol. 2010, 24:359-369.
21. Ouellet V., Guyot M.C., Le Page C., Filali-Mouhim A., Lussier C., Tonin P.N., Provencher D.W., Mes-Masson A.M. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int. J. Cancer 2006, 119:599-607.
22. Nguyen L.P., Bradfield C.A. The search for endogenous activators of the aryl hydrocarbon receptor. Chem. Res. Toxicol. 2008, 21:102-116.
23. Song J., Clagett-Dame M., Peterson R.E., Hahn M.E., Westler W.M., Sicinski R.R., DeLuca H.F. A ligand for the aryl hydrocarbon receptor isolated from lung. Proc. Natl. Acad. Sci. USA 2002, 99:14694-14699.
24. Henry E.C., Bemis J.C., Henry O., Kende A.S., Gasiewicz T.A. A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo. Arch. Biochem. Biophys. 2006, 450:67-77.
25. Quintana F.J., Murugaiyan G., Farez M.F., Mitsdoerffer M., Tukpah A.M., Burns E.J., Weiner H.L. From the Cover: an endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 2010, 107:20768-20773.
26. Dai C., Jiang Y.Z., Li Y., Wang K., Liu P., Patankar M.S., Zheng J. Expression and roles of Slit/Robo in human ovarian cancer. Histochem. Cell Biol. 2011, 135:475-485.
27. Jiang Y.Z., Wang K., Fang R., Zheng J. Expression of aryl hydrocarbon receptor in human placentas and fetal tissues. J. Histochem. Cytochem. 2010, 58:679-686.
28. Ayhan A., Kurman R.J., Yemelyanova A., Vang R., Logani S., Seidman J.D., Shih IeM Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am. J. Surg. Pathol. 2009, 33:1220-1224.
29. Soslow R.A. Histologic subtypes of ovarian carcinoma: an overview. Int. J. Gynecol. Pathol. 2008, 27:161-174.
30. McCluggage W.G. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011, 43:420-432.
31. Hagopian G.S., Mills G.B., Khokhar A.R., Bast R.C., Siddik Z.H. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane) (trans-diacetato) (dichloro)-platinum(IV). Clin. Cancer Res. 1999, 5:655-663.
32. Lau K.M., Mok S.C., Ho S.M. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc. Natl. Acad. Sci. USA 1999, 96:5722-5727.
33. Song Y., Wang K., Chen D.B., Magness R.R., Zheng J. Suppression of protein phosphatase 2 differentially modulates VEGF- and FGF2-induced signaling in ovine fetoplacental artery endothelial cells. Placenta 2009, 30:907-913.
34. Wang K., Song Y., Chen D.B., Zheng J. Protein phosphatase 3 differentially modulates vascular endothelial growth factor- and fibroblast growth factor 2-stimulated cell proliferation and signaling in ovine fetoplacental artery endothelial cells. Biol. Reprod. 2008, 79:704-710.
35. Jobe S.O., Ramadoss J., Koch J.M., Jiang Y.Z., Zheng J., Magness R.R. Estradiol-17beta and its cytochrome p450- and catechol-o-methyltransferase-derived metabolites stimulate proliferation in uterine artery endothelial cells: role of estrogen receptor-alpha versus estrogen receptor-beta. Hypertension 2010, 55:1005-1011.
36. Alley M.C., Hollingshead M.G., Dykes D.J., Waud W.R. Human tumor xegograft models in NCI drug development. Anticancer Drug Development Guide: Prelinical Screening, Clinical Trials, and Approval 2004, 125-152. Humana Press, Totowa. B.A. Teicher, P.A. Andrew (Eds.).
37. Juan S.H., Lee J.L., Ho P.Y., Lee Y.H., Lee WS W.S. Antiproliferative and antiangiogenic effects of 3-methylcholanthrene, an aryl-hydrocarbon receptor agonist, in human umbilical vascular endothelial cells. Eur. J. Pharmacol. 2006, 530:1-8.
38. Tan Z., Chang X., Puga A., Xia Y. Activation of mitogen-activated protein kinases (MAPKs) by aromatic hydrocarbons: role in the regulation of aryl hydrocarbon receptor (AHR) function. Biochem. Pharmacol. 2002, 64:771-780.
39. Tan Z., Huang M., Puga A., Xia Y. A critical role for MAP kinases in the control of Ah receptor complex activity. Toxicol. Sci. 2004, 82:80-87.
40. Wu R., Zhang L., Hoagland M.S., Swanson H.I. Lack of the aryl hydrocarbon receptor leads to impaired activation of AKT/protein kinase B and enhanced sensitivity to apoptosis induced via the intrinsic pathway. J. Pharmacol. Exp. Ther. 2007, 320:448-457.
41. Ohtake F., Fujii-Kuriyama Y., Kawajiri K., Kato S. Cross-talk of dioxin and estrogen receptor signals through the ubiquitin system. J. Steroid. Biochem. Mol. Biol. 2011, 127:102-117.